Application of polypeptide or related biological material thereof in inhibition of osteoclast differentiation

By using a polypeptide with an amino acid sequence such as SEQ ID NO:1 to inhibit osteoclast differentiation, the problems of large side effects, long treatment course, long time consumption and slow effect in the existing osteoporosis treatment are solved, and efficient and safe osteoporosis treatment and prevention are achieved.

CN120939194APending Publication Date: 2025-11-14HAOYIKANG BIOMATERIALS (GUANGZHOU) CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202510877804.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-06-27
Publication Date
2025-11-14

AI Technical Summary

Technical Problem

Existing technologies for treating osteoporosis suffer from problems such as significant side effects, long treatment courses, long treatment times, high risks, or slow results, and there is a lack of effective peptide therapy methods.

Method used

Products for treating and/or preventing osteoporosis, including pharmaceuticals and oral care products, are prepared by using peptides or related biological materials with amino acid sequences such as those shown in SEQ ID NO:1, by inhibiting osteoclast differentiation.

Benefits of technology

It significantly inhibits osteoclast differentiation, effectively treats and/or prevents osteoporosis, and is suitable for preparing various osteoporosis products, reducing side effects and improving treatment efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120939194A_ABST
    Figure CN120939194A_ABST
Patent Text Reader

Abstract

The invention provides application of polypeptide or related biological materials thereof in inhibition of osteoclast differentiation. The polypeptide with the amino acid sequence as shown in SEQ ID NO: 1 or related biological materials thereof can remarkably inhibit osteoclast differentiation, further effectively treat and / or prevent osteoporosis and is suitable for preparing products for treating and / or preventing osteoporosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biopharmaceutical manufacturing technology. More specifically, it relates to the application of peptides or related biomaterials in inhibiting osteoclast differentiation. Background Technology

[0002] Osteoporosis is a systemic skeletal disease characterized by decreased bone mass, deterioration of bone microstructure, increased bone fragility, and decreased bone strength. This makes bones prone to fracture even under minor external forces, severely impacting patients' quality of life. Its occurrence is usually the result of multiple factors, including aging, gender differences (significant decline in estrogen levels after menopause in women), genetic factors, unhealthy lifestyle habits (such as lack of exercise, smoking, excessive alcohol consumption, excessive caffeine intake, and malnutrition, especially calcium and vitamin D deficiency), and the effects of certain diseases and medications (such as hyperparathyroidism, rheumatoid arthritis, and long-term use of glucocorticoids).

[0003] Osteoporosis can be classified according to the location of occurrence, such as: (1) Jaw osteoporosis: It often occurs in middle-aged and elderly people with long-term calcium deficiency, which may lead to decreased tooth stability, tooth displacement or loss, etc., affecting chewing function, and thus affecting digestion and nutrient absorption; tooth loss may also affect facial aesthetics and pronunciation; (2) Spinal osteoporosis: It is one of the most common types of osteoporotic fractures, commonly occurring in the vertebral body, leading to vertebral compression fractures, manifested as shortened height, kyphosis and back pain, etc.; (3) Wrist osteoporosis : It is common in postmenopausal women who fall and brace themselves with their hands, resulting in distal radius fractures. Symptoms include wrist swelling, pain and limited mobility; (4) Hip osteoporosis: It is common in elderly people who fall, mainly affecting the femoral neck or intertrochanteric region. Hip fractures have a high disability and mortality rate, seriously affecting the quality of life of patients; (5) Systemic osteoporosis: It is common in patients who use glucocorticoids for a long time, have endocrine diseases or severe malnutrition. It is characterized by a reduction in bone mass that is widely distributed throughout the skeleton without any obvious preference for a specific location.

[0004] Currently, the main methods used to treat osteoporosis include: (1) Western medicine treatment: symptomatic treatment is often used, such as taking some antipyretic and analgesic drugs when osteoporosis is painful, B vitamins can be used for numbness, and local aspiration or local injection can be given for joint swelling and effusion; however, this symptomatic treatment cannot fundamentally solve the cause of osteoporosis, and some drugs may have side effects, such as antipyretic and analgesic drugs may irritate the gastrointestinal tract; (2) Traditional Chinese medicine treatment: to cure osteoporosis from the pathological perspective, but the effect is slow and the course of treatment is long; (3) Physical therapy: such as pulsed electromagnetic field therapy, ultrasound therapy, etc., which help Relieve pain and promote fracture healing, but the treatment process may need to be repeated multiple times and is relatively time-consuming; (4) Surgical treatment: When conservative treatment is ineffective and the condition is more serious and seriously affects the patient's life, surgical treatment can be considered, but the surgical risk is high, and there may be complications such as infection and bleeding. The recovery time after surgery is long and may also affect local function; (5) Basic treatment: This includes adjusting lifestyle, such as quitting smoking, limiting alcohol, moderate exercise, and balanced diet. However, this method requires patients to adhere to it for a long time, and the effect is relatively slow. Moreover, for patients who have already developed severe osteoporosis, it is difficult to achieve the ideal treatment effect by relying solely on basic treatment.

[0005] Peptides are compounds formed by linking multiple α-amino acids together through a peptide chain. Due to their significant advantages such as having a variety of biological activities, rapid onset of action, and being less likely to cause adverse reactions and drug resistance, they have gradually gained widespread attention in the pharmaceutical field. However, there are still relatively few peptides that can treat and / or prevent osteoporosis. Summary of the Invention

[0006] This invention addresses the shortcomings of existing technologies by providing the application of polypeptides (amino acid sequences as shown in SEQ ID NO:1) or related biomaterials in inhibiting osteoclast differentiation. Since an increase in the number and activity of osteoclasts leads to bone resorption exceeding bone formation, resulting in decreased bone density, destruction of bone microstructure, and consequently osteoporosis, increasing the risk of fractures, the polypeptides or related biomaterials of this invention can effectively treat and / or prevent osteoporosis by inhibiting osteoclast differentiation, and are suitable for preparing products for the treatment and / or prevention of osteoporosis.

[0007] The first objective of this invention is to provide the use of polypeptides or related biomaterials in the preparation of products for the treatment and / or prevention of osteoporosis.

[0008] A second objective of this invention is to provide the use of active peptides or related biomaterials in the preparation of products for the treatment and / or prevention of osteoporosis.

[0009] The above-mentioned objective of this invention is achieved through the following technical solution:

[0010] This invention has discovered that polypeptides with amino acid sequences as shown in SEQ ID NO:1 or related biomaterials can significantly inhibit osteoclast differentiation. Furthermore, an increase in the number and activity of osteoclasts leads to bone resorption exceeding bone formation, resulting in decreased bone density, destruction of bone microstructure, and ultimately osteoporosis. Therefore, the application of polypeptides with amino acid sequences as shown in SEQ ID NO:1 or related biomaterials in the preparation of products for the treatment and / or prevention of osteoporosis should be within the scope of protection of this invention.

[0011] Preferably, the relevant biological material is a nucleic acid molecule capable of expressing the polypeptide, or an expression cassette, recombinant plasmid, recombinant bacteria, or recombinant cell containing the nucleic acid molecule.

[0012] Preferably, the osteoporosis is one or more of the following: jaw osteoporosis, spinal osteoporosis, wrist osteoporosis, hip osteoporosis, and systemic osteoporosis.

[0013] Preferably, the product is one of the following: pharmaceuticals, oral care products, or oral health products.

[0014] Preferably, the drug is one or more of the following: oral liquid, tincture, tincture, aerosol, powder, injection, sterile powder for injection, and suppository. The types of the above preparations can be understood according to the relevant definitions in *Pharmaceutics* (6th Edition, People's Medical Publishing House, Cui Fude), and the preparation of the above preparations can be carried out according to the relevant preparation methods in *Pharmaceutics* (6th Edition, People's Medical Publishing House, Cui Fude).

[0015] Furthermore, the medicine also contains excipients.

[0016] Furthermore, the excipients are solid lubricants (such as stearic acid and / or magnesium stearate, used to reduce friction and ensure successful drug manufacturing), vegetable oils (such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and / or cocoa butter, used as solvents or carriers to help drug components dissolve or disperse better), polyols (such as propylene glycol, glycerin, sorbitol, mannitol, and / or polyethylene glycol, used to improve drug stability, prevent drug dehydration or deterioration during storage, and also to improve drug taste and solubility), and alginic acid (to maintain the physical stability of the drug and prevent...). Drug components include: (1) prevents drug particle sedimentation or aggregation; (2) emulsifiers (such as Tween and / or polyoxyethylene castor oil, used to reduce interfacial tension, promote emulsification of the dispersed phase, and maintain emulsion stability); (3) wetting agents (such as sodium lauryl sulfate, used to help drug components disperse and dissolve better); (4) colorants (used to improve the appearance and color of drugs, making them easier to identify and distinguish); (5) flavoring agents (used to improve the taste of drugs and increase patient medication compliance); and (6) tableting agents (facilitating the compression of loose granular substances into solid tablets, making them convenient for patients to take and carry, and also improving drug stability and bioavailability). The following are listed: 1) Stabilizers (to increase the physical stability of the drug and prevent it from deteriorating or degrading during storage or transportation), 2) Antioxidants (to prevent the drug from deteriorating due to oxidation during storage or use and extend its shelf life), 3) Isotonic salt solutions (to adjust the osmotic pressure of the drug to meet the physiological requirements of the human body, thereby reducing irritation and adverse reactions), 4) Phosphate buffer solutions (to adjust the pH value of the drug to meet the physiological requirements of the human body, thereby reducing irritation and adverse reactions), 5) Sugars (such as lactose, glucose, and / or sucrose, to help the drug components disperse and dissolve better, while providing necessary energy support), 6) Starches (such as corn starch and / or potato starch, to help tablets disintegrate rapidly after administration and release the drug components, thereby improving the bioavailability of the drug), 7) Cellulose and its derivatives (such as sodium carboxymethyl cellulose, ethyl cellulose, and / or methyl cellulose, to improve the compressibility and formability of the drug, and also to control the release rate of the drug), 8) Binders (such as gelatin, to help the drug components bind together better), and 9) Lubricants (such as talc, to reduce friction in the drug). The type of excipient can be selected based on the need to improve drug stability, activity, and / or bioavailability.

[0017] Preferably, the oral care product is one or more of the following: oral care liquid, oral lozenges, oral sprays, oral patches, oral powders, oral gels, oral sustained-release agents, mouthwash, toothpaste, and mouthwash effervescent tablets.

[0018] Preferably, the oral care product is one or more of the following: oral care solution, oral lozenges, oral spray, oral patch, oral powder, oral gel, oral sustained-release agent, mouthwash, toothpaste, and mouthwash effervescent tablets.

[0019] Furthermore, the oral care products and oral health products also contain excipients.

[0020] Furthermore, the excipients include solvents (such as glycerin, propylene glycol, and / or ethanol, used to dissolve raw materials for ease of use and storage), flavorings (such as peppermint flavoring, used to enhance the aroma and taste of oral care and oral health products, improving the user's sensory experience), preservatives (such as potassium sorbate, sodium benzoate, methylparaben, and / or propylparaben, used to prevent the growth of microorganisms in oral care and oral health products, extending their shelf life), antibacterial agents (such as cetylpyridinium chloride, chlorhexidine gluconate, and / or benzalkonium chloride, used to inhibit or kill harmful microorganisms in the oral cavity, helping to maintain oral health), and pH adjusters (such as disodium hydrogen phosphate, sodium dihydrogen phosphate, and / or sodium citrate, used to adjust the pH of oral care and oral health products to meet their requirements). The excipients used in oral care and hygiene products include one or more of the following: excipients to meet the physiological needs of the oral environment and reduce irritation to oral tissues; thickeners (such as poloxamer 407, used to increase the viscosity of oral care and hygiene products, improve the user experience, and also improve the stability of oral care and hygiene products, preventing separation or sedimentation); sweeteners (such as sucralose, sodium saccharin, sorbitol, xylitol, and / or maltitol, used to increase the sweetness of oral care and hygiene products, enhancing the user's sensory experience); cooling agents (such as menthol and its derivatives, used to increase the cooling sensation of oral care and hygiene products, enhancing the user's sensory experience); and surfactants (such as sodium lauryl sulfate and / or sodium lauroyl sarcosinate, used to reduce the surface tension of oral care and hygiene products, enhancing cleaning effectiveness). The type of excipient can be selected based on the need to improve the stability, safety, effectiveness, or user experience of oral care and hygiene products.

[0021] Based on this, the present invention also seeks protection for the use of active peptides or related biomaterials in the preparation of products for the treatment and / or prevention of osteoporosis, wherein the active peptides have more than 85% homology with the polypeptides whose amino acid sequences are as shown in SEQ ID NO:1.

[0022] Preferably, the relevant biological material is a nucleic acid molecule capable of expressing the active peptide, or an expression cassette, recombinant plasmid, recombinant bacteria, or recombinant cell containing the nucleic acid molecule.

[0023] Preferably, the osteoporosis is one or more of the following: jaw osteoporosis, spinal osteoporosis, wrist osteoporosis, hip osteoporosis, and systemic osteoporosis.

[0024] Preferably, the product is one of the following: pharmaceuticals, oral care products, or oral health products.

[0025] Preferably, the drug is one or more of the following: oral liquid, tincture, tincture, aerosol, powder, injection, sterile powder for injection, and suppository. The types of the above preparations can be understood according to the relevant definitions in *Pharmaceutics* (6th Edition, People's Medical Publishing House, Cui Fude), and the preparation of the above preparations can be carried out according to the relevant preparation methods in *Pharmaceutics* (6th Edition, People's Medical Publishing House, Cui Fude).

[0026] Preferably, the oral care product is one or more of the following: oral care liquid, oral lozenges, oral sprays, oral patches, oral powders, oral gels, oral sustained-release agents, mouthwash, toothpaste, and mouthwash effervescent tablets.

[0027] Preferably, the oral care product is one or more of the following: oral care solution, oral lozenges, oral spray, oral patch, oral powder, oral gel, oral sustained-release agent, mouthwash, toothpaste, and mouthwash effervescent tablets.

[0028] Furthermore, the oral care products and oral health products also contain excipients.

[0029] Furthermore, the excipients include solvents (such as glycerin, propylene glycol, and / or ethanol, used to dissolve raw materials for ease of use and storage), flavorings (such as peppermint flavoring, used to enhance the aroma and taste of oral care and oral health products, improving the user's sensory experience), preservatives (such as potassium sorbate, sodium benzoate, methylparaben, and / or propylparaben, used to prevent the growth of microorganisms in oral care and oral health products, extending their shelf life), antibacterial agents (such as cetylpyridinium chloride, chlorhexidine gluconate, and / or benzalkonium chloride, used to inhibit or kill harmful microorganisms in the oral cavity, helping to maintain oral health), and pH adjusters (such as disodium hydrogen phosphate, sodium dihydrogen phosphate, and / or sodium citrate, used to adjust the pH of oral care and oral health products to meet their requirements). The excipients used in oral care and hygiene products include one or more of the following: excipients to meet the physiological needs of the oral environment and reduce irritation to oral tissues; thickeners (such as poloxamer 407, used to increase the viscosity of oral care and hygiene products, improve the user experience, and also improve the stability of oral care and hygiene products, preventing separation or sedimentation); sweeteners (such as sucralose, sodium saccharin, sorbitol, xylitol, and / or maltitol, used to increase the sweetness of oral care and hygiene products, enhancing the user's sensory experience); cooling agents (such as menthol and its derivatives, used to increase the cooling sensation of oral care and hygiene products, enhancing the user's sensory experience); and surfactants (such as sodium lauryl sulfate and / or sodium lauroyl sarcosinate, used to reduce the surface tension of oral care and hygiene products, enhancing cleaning effectiveness). The type of excipient can be selected based on the need to improve the stability, safety, effectiveness, or user experience of oral care and hygiene products.

[0030] The present invention has the following beneficial effects:

[0031] The polypeptide or related biomaterial of the present invention, whose amino acid sequence is shown in SEQ ID NO:1, can significantly inhibit osteoclast differentiation, thereby effectively treating and / or preventing osteoporosis, and is suitable for preparing products for treating and / or preventing osteoporosis. Attached Figure Description

[0032] Figure 1 The results of TRAP staining of cells.

[0033] Figure 2 The statistical results show the percentage of osteoclast area in the RANKL group and the RANKL+ peptide group. Detailed Implementation

[0034] The present invention will be further described below with reference to the accompanying drawings and specific embodiments, but the embodiments do not limit the present invention in any way. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in this technical field.

[0035] Unless otherwise specified, all reagents and materials used in the following examples are commercially available.

[0036] Example 1 Synthesis of polypeptides

[0037] The company was commissioned to synthesize a polypeptide (amino acid sequence as shown in SEQ ID NO:1: GLDWWQL).

[0038] Example 2: The peptide can treat and / or prevent osteoporosis.

[0039] I. Experimental Methods

[0040] (1) Days 1-2: RAW264.7 mouse macrophages were seeded in α-MEM high glucose medium containing 10% (v / v) FBS and transferred to 48-well plates, ensuring 500 μL of medium per well and a cell density of 5000 cells / well.

[0041] Add the cells according to the following groups:

[0042] ①Sham group: No special treatment;

[0043] ②RANKL group: RANKL (osteoclast differentiation factor) was added to a final concentration of 100 ng / mL;

[0044] ③Sham+ polypeptide group: Add the polypeptide obtained in Example 1 to make a final concentration of 25 μM;

[0045] ④RANKL+ Peptide Group: Add RANKL to a final concentration of 100 ng / mL; and add the peptide obtained in Example 1 to a final concentration of 25 μM.

[0046] After adding the samples, all four groups of cells were cultured at 37°C and 5% CO2 for 2 days.

[0047] (2) Days 3-5: Replace the culture medium in the 48-well plate with fresh culture medium and add samples again:

[0048] ①Sham group: No special treatment;

[0049] ②RANKL group: RANKL was added to make the final concentration of the newly added RANKL 100ng / mL;

[0050] ③Sham+ polypeptide group: Add the polypeptide obtained in Example 1 to make the final concentration of the newly added polypeptide 25 μM;

[0051] ④ RANKL + Peptide Group: Add RANKL to make the final concentration of the newly added RANKL 100 ng / mL; and add the peptide obtained in Example 1 to make the final concentration of the newly added peptide 25 μM.

[0052] After adding the samples, all four groups of cells were cultured at 37°C and 5% CO2 for 3 days.

[0053] II. Experimental Results

[0054] On day 4 of induction, small osteoclasts were observed under an optical microscope.

[0055] On day 5 of induction, osteoclasts were stained and identified according to the instructions of the TRAP staining kit. They were observed and photographed under a light microscope (cells with ≥3 nuclei were considered TRAP-positive cells, i.e., osteoclasts); results are as follows. Figure 1 As shown in the figure), the percentage of osteoclast area in the RANKL group and the RANKL+ peptide group was calculated using ImageJ software (results are shown in the figure). Figure 2 (As shown).

[0056] As can be seen, compared with the Sham group, the RANKL group showed a significant increase in osteoclast formation, while the RANKL+peptide group with added peptide intervention could significantly inhibit the increase in osteoclast formation caused by RANKL. This indicates that the peptide with the amino acid sequence shown in SEQ ID NO:1 of the present invention can significantly inhibit the differentiation of macrophages into osteoclasts induced by RANKL, thereby effectively treating and / or preventing osteoporosis, and is suitable for preparing products for treating and / or preventing osteoporosis.

[0057] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.

Claims

1. The use of polypeptides or related biomaterials in the preparation of products for the treatment and / or prevention of osteoporosis, characterized in that, The amino acid sequence of the polypeptide is shown in SEQ ID NO:

1.

2. The application according to claim 1, characterized in that, The relevant biological material is a nucleic acid molecule that can express the polypeptide, or an expression cassette, recombinant plasmid, recombinant bacteria, or recombinant cell containing the nucleic acid molecule.

3. The application according to claim 1, characterized in that, The osteoporosis mentioned is one or more of the following: jaw osteoporosis, spinal osteoporosis, wrist osteoporosis, hip osteoporosis, and systemic osteoporosis.

4. The application according to claim 1, characterized in that, The product is one of the following: pharmaceuticals, oral care products, or oral health products.

5. The application according to claim 4, characterized in that, The medicine is one or more of the following: oral liquid, tincture, aerosol, powder, injection, sterile powder for injection, and suppository.

6. The application according to claim 4, characterized in that, The oral care products mentioned are one or more of the following: oral care liquid, oral lozenges, oral sprays, oral patches, oral powders, oral gels, oral sustained-release agents, mouthwash, toothpaste, and mouthwash effervescent tablets.

7. The application according to claim 4, characterized in that, The oral care products mentioned are one or more of the following: oral care liquid, oral lozenges, oral sprays, oral patches, oral powders, oral gels, oral sustained-release agents, mouthwash, toothpaste, and mouthwash effervescent tablets.

8. The use of bioactive peptides or related biomaterials in the preparation of products for the treatment and / or prevention of osteoporosis, characterized in that, The active peptide has more than 85% homology with the polypeptide whose amino acid sequence is shown in SEQ ID NO:

1.

9. The application according to claim 8, characterized in that, The relevant biological material is a nucleic acid molecule that can express the active peptide, or an expression cassette, recombinant plasmid, recombinant bacteria, or recombinant cell containing the nucleic acid molecule.

10. The application according to claim 8, characterized in that, The osteoporosis mentioned is one or more of the following: jaw osteoporosis, spinal osteoporosis, wrist osteoporosis, hip osteoporosis, and systemic osteoporosis.

Citation Information

Cited By

  • Polypeptide and use thereof in preparation of streptococcus mutans inhibitor

    WO2026170856A1